ACAD
ACADIA Pharmaceuticals Inc.26.80
-0.46-1.69%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.53BP/E (TTM)
17.29Basic EPS (TTM)
1.55Dividend Yield
0%Recent Filings
8-K
Board member resigns amicably
Acadia Pharmaceuticals announced the resignation of board member Daniel B. Soland, effective October 30, 2025, along with his role as Chair of the Nominating and Corporate Governance Committee. The move stems from his notification on October 28, 2025, with no disputes over company operations or policies. This change prompts a search for a new director. Smooth transition ahead.
10-Q
Q2 FY2025 results
Acadia Pharmaceuticals posted solid Q2 FY2025 results, with net product sales climbing 9.4% y/y to $264.6M, driven by NUPLAZID's 7.0% y/y gain to $168.5M and DAYBUE's 13.6% y/y increase to $96.1M; YTD sales rose 13.6% y/y to $508.9M. Gross margin held steady at 92.2% q/q and y/y, while operating income edged up 6.3% y/y to $32.4M, but diluted EPS dipped 20.0% y/y to $0.16 amid higher R&D and SG&A spends. YTD operating income grew 13.2% y/y to $51.7M, with diluted EPS flat y/y at $0.27, reconciling to 168.2M diluted shares. Cash from operations surged 55.9% y/y to $84.3M YTD, ending with $253.6M in cash equivalents and $508.4M in investments, no debt. No M&A or impairments noted. Regulatory risks loom from ongoing patent litigation over NUPLAZID generics.
8-K
Acadia Q2 revenues rise 9%
Acadia Pharmaceuticals reported Q2 2025 total revenues of $264.6 million, up 9% year-over-year, driven by NUPLAZID sales of $168.5 million (up 7%) and DAYBUE sales of $96.1 million (up 14%), reflecting strong patient growth and commercial execution. The company raised its full-year NUPLAZID guidance to $665-690 million while reiterating other targets, bolstered by patent wins securing exclusivity through 2038 and completed enrollment in the COMPASS PWS Phase 3 trial with results due early Q4. Momentum builds. Yet, net income dipped to $26.7 million from $33.4 million due to a higher tax rate.
8-K
Court upholds NUPLAZID patent
Acadia Pharmaceuticals scored a key win on June 9, 2025, when the U.S. Court of Appeals for the Federal Circuit upheld the validity of its NUPLAZID '740 composition of matter patent in litigation against MSN Laboratories. This affirmance bolsters Acadia's intellectual property defenses for the pimavanserin-based drug. The ruling fortifies market exclusivity. Yet risks from ongoing lawsuits persist.
8-K
Annual meeting elects directors
Acadia Pharmaceuticals held its 2025 Annual Meeting on May 29, electing Catherine Owen Adams, Laura A. Brege, and Elizabeth A. Garofalo, M.D., as Class III directors until 2028, with strong support—Adams garnered 142 million for votes amid 2.9 million withheld. Stockholders advisory approved executive compensation by 142 million for versus 2.8 million against. Ernst & Young LLP's appointment as auditor passed overwhelmingly at 154 million for. Routine governance signals steady board continuity.
AVXL
Anavex Life Sciences Corp.
4.02-0.12
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
JAZZ
Jazz Pharmaceuticals plc
169.73+0.20
NERV
Minerva Neurosciences, Inc
4.17+0.13
NEUP
Neuphoria Therapeutics Inc.
3.90+0.07
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
RYTM
Rhythm Pharmaceuticals, Inc.
112.45-0.07
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02
XENE
Xenon Pharmaceuticals Inc.
43.00-0.60
ZVRA
Zevra Therapeutics, Inc.
8.12-0.05